SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015203796> ?p ?o ?g. }

Showing items 1 to 100 of ±194 with 100 items per page.

W2015203796 endingPage "340" @default.
W2015203796 startingPage "324" @default.
W2015203796 abstract "Clark et al.1 described the concept of tumor progression in malignant melanoma (MM). Subsequent studies have shown that metastasis is exclusively associated with a specific pattern of tumor growth within the dermis, which Clark et al.2 termed the vertical growth phase. Most melanomas evolve through an initial stage termed the radial growth phase (in situ or ‘microinvasive’ melanoma) in which the probability of cure approaches 100%.3 Despite recent improvements in the earlier recognition of cutaneous melanoma, by the time of diagnosis, approximately 70% of melanomas have evolved into vertical growth phase or ‘tumorigenic melanoma’. Thus, assessment of prognostic parameters is of value only in vertical growth phase lesions. However, this concept of radial and vertical growth phase is not universally accepted.4 Several clinical and pathologic factors that influence the progression and behavior of melanoma have been identified. These factors include tumor thickness, ulceration, anatomic site of the primary tumor, age, gender, level of invasion, mitotic rate, tumor-infiltrating lymphocytes (TILs), histologic regression, microscopic satellites, histologic subtype, vascular invasion, and tumor cell type.3,5–14 The first three are thought to be dominant factors that predict survival in patients with stage I and II primary melanomas.3 To date, most studies have shown that the single attribute best predictive of clinical outcome for a given patient is the depth of tumor invasion (Breslow thickness), which is the most powerful independent prognostic factor.7–14 It has become the gold standard for stratifying patients according to risk of metastatic disease. However, these studies also point out that in some cases, tumor thickness has not been as accurate an indicator of biologic behavior of MM as expected. Some patients with thick melanoma do surprisingly well and survive far longer than expected, whereas others with thin melanoma have a more aggressive course of disease.14 Distinguishing patients who truly have minimal risk of metastasis from patients at greater risk of developing progressive disease is crucial for treatment planning. Therefore, additional prognostic variables are needed with improved specificity and predictive value for melanoma patients. Rapidly expanding knowledge about mechanisms of tumor progression in melanocytic tumors and the advanced molecular biology techniques emerging in the past few years have helped in the search for such markers. So far, a number of biological markers, in addition to traditional histopathology, have been shown to serve as independent prognostic markers for patients with cutaneous melanoma. The markers with prognostic value for melanoma, especially those that can be used on routine formalin-fixed, paraffin-embedded materials by using immunohistochemistry (IHC), or in the diagnostic molecular pathology laboratory, will be reviewed in this article. Therefore, we have subgrouped these prognostic markers into three categories: (i) tissue markers, (ii) serological markers, and (iii) molecular markers. A tremendous number of melanoma markers, which provide insight into the prognosis of melanoma lesions, have been studied on tissue by immunohistochemical methods. Many of these markers can be broadly categorized according to their mechanisms of action. They are reviewed in this article as follows: (i) markers of cellular proliferation, oncogenes and tumor suppressor genes; (ii) extracellular matrix degrading enzymes; (iii) cell adhesion molecules; and (iv) other new markers. These markers are primarily experimental and have not been used on a routine basis. In several malignant neoplasms, proliferative activity is known to be related to the development of metastatic disease and to influence patient survival.15 One of the easiest and most reliable methods of assessing the degree of proliferative activity is the Ki-67 index.16 The Ki-67 antigen is a non-histone protein that can be detected in the nucleus of cells during late G1, S, G2, and M phases, which makes it a more sensitive marker of the proliferation index in tissues than the mitotic index. The prognostic significance of the Ki-67 index detected by IHC has been shown in several tumor types.16 In melanoma, most studies have shown the Ki-67 index as a useful prognostic marker for melanoma progression.17–21 An elevated Ki-67 expression was significantly and independently associated with the risk of metastatic disease or decreased overall survival in these studies. However, this association seems to occur only in thick primary MM (at least > 1.5 mm)18–22 but not in thin lesions.19,22 One study further demonstrated that for MM thicker than 4.00 mm, a new prognostic parameter, ‘proliferation-based prognostic index’ (tumor thickness × Ki-67 index/100), conveys an independent prognostic significance.22 On the contrary, some studies failed to demonstrate the prognostic value of Ki-67 in primary cutaneous MM.23,24 In addition to its prognostic value, the Ki-67 index has been used as an aid to the diagnosis of malignant of melanoma.25,26 The Ki-67 index exhibited a significant difference between benign melanocytic nevi, Spitz nevi, and melanoma. Furthermore, one study showed a significant difference in the Ki-67 index of vertical growth phase MM compared with radial growth phase melanomas that had a similar proliferative index to those of melanocytic nevi.26 These studies suggest that determination of the proliferative activity in melanocytic lesions may usefully complement conventional histology to recognize melanoma, but not distinguish it from benign melanocytic lesions. p53 is a tumor suppressor gene. The overexpression of p53 detected by immunostaining for p53 protein has been reported as a prognostic indicator for many tumors. Expression of p53 has been shown to correlate with Ki-67 overexpression and with disease progression in melanoma.20,26–28 In melanoma, the abnormalities of p53 expression seem to be demonstrated only in primary, thick (> 1.5 mm), invasive and metastatic melanoma,20,26–28 which is similar to that reported in Ki-67. One study, which compared thick (> 3 mm) primary melanomas with different clinical outcomes, demonstrated that overexpression of p53 was significantly associated with metastasis and death.25 However, reports regarding abnormal expression of p53 protein and p53 mutation in cutaneous MM are greatly contradictory,29–31 with some studies failing to find a link between immunohistochemical detection of p53 protein and prognosis in cutaneous melanoma. Thus, the clinical prognostic value of p53 protein expression remains uncertain. Another tumor suppressor gene, the cyclin-dependent kinase inhibitor-2 (CDKN2A) or p16 gene, which maps to chromosome 9p21, has been shown to be deleted or mutated in a high percentage of melanoma tumor cell lines.32 Mutations have also been frequently reported in the germline of familial melanoma members.32 Additionally, recent studies indicate that p16 alterations such as homozygous deletion of CDKN2A, loss of heterozygosity of 9p21 and mutations occur frequently in sporadic melanomas.33,34 Thus, the role of this gene in melanoma progression has been investigated by immunolabeling the expressed product, p16INK4a, on paraffin-embedded melanoma tissue.21,33–40 p16INK4a functions as a negative regulator of cell cycle progression and as a tumor suppressor by inhibiting the catalytic activity through the G1-S phase cell cycle checkpoint. Immunolabeling of p16INK4a is distributed to both cytoplasm and nuclei of normal and transformed melanocytes21,35,36 but is more accurately represented by nuclear staining.21 Not surprisingly, uniform immunolabeling of p16INK4a was seen in benign melanocytic nevi33,36–38 and dysplastic nevi.38 Loss of p16 protein expression by IHC was seen in primary cutaneous melanoma and has been correlated with advanced stages of melanoma progression.33,36–38 Initial studies showed that p16INK4a protein expression reduction in melanoma cells occurred only in the invasive and metastatic stages of malignant melanoma, by 38–62%,33,36,37 and was associated with significant risk of relapse in a multivariate analysis39 and with a trend to worse prognosis in a separate study.40 The data are conflicting regarding the p16 gene as an initiating event in melanoma development. Existing observations indicate that in melanoma in situ, either there are no alterations in p16 protein expression by immunolabeling or there is reduced expression of either the protein37,38 or mRNA.38 Once invasive or metastatic disease has supervened, several studies have confirmed progressive loss of p16 with increasing stage of melanoma.21,37,38 Findings in one recent study indicated that loss of nuclear p16 protein expression identified an aggressive subset of vertical growth melanoma by showing that absent or minimal nuclear staining significantly predicted decreased patient survival, with 37 and 67% estimated 10-year survival rates, respectively.21 In this study, reduced p16 expression was an independent prognosis factor, and associated with increased tumor cell proliferation (Ki-67 index). It must be noted, however, that p16INK4a protein expression was normal in some fully evolved melanomas, raising the question of whether or not the decreased p16INK4a expression in invasive melanomas will have clinical prognostic value.21 Other protein family members of cyclin-dependent kinase (CDK) inhibitors, such as p21WAF1 and p27KIP1, have also been studied for their expression in melanoma by immunohistochemistry. Overall, p21WAF1 and p27KIP1 levels were found to be low or undetectable in the majority of benign melanocytic lesions,36 with higher expression seen in malignant melanomas.36,41 Although an association of increased expression of p21 with Clark level and Breslow thickness was found, no correlation to clinical stage or patient prognosis was demonstrated with either p21 or p27.36 Moreover, the regulatory subunits of cyclin-dependent kinase 4 (CDK4), especially the d-type cyclins (D1, D2 and D3), have been investigated for their potential value as prognostic indicators for melanoma. Limited studies revealed elevated cyclin D1 and D3 protein expression in melanomas and metastatic melanomas compared with low or absent expression in benign nevi.34,42,43 However, only increased expression of cyclin D3 expression was an indicator of early relapse and decreased overall survival for patients with superficial spreading melanoma, but not nodular melanoma.42 Thus, the prognostic value of cyclins needs to be further investigated. Over the last decade it has been appreciated that oncogenes that are involved in the transformation of normal cells into cancer cells play a pivotal role in determining the biology of malignant disease and thus clinical outcome. One particular oncogene, c-myc, is known to be deregulated in a number of human malignancies. The c-myc oncogene produces a nuclear oncoprotein, which appears to act by increasing the rate of cellular proliferation and the metastatic potential of tumor cells.44 Recent works have shown c-myc expression to be a marker of poor prognosis in head and neck cancer and cervical carcinoma.45,46 In addition, the measurement of c-myc oncoprotein by flow cytometry has recently been noted to provide prognostic stratification in primary and metastatic melanoma,47 subungual melanoma,48 acral lentiginous melanoma,49 and regional metastatic disease.50 However, the results measured by IHC were controversial.51,52 Expression of c-myc oncoprotein was higher in metastatic than in primary melanoma, but it predicted clinically poor outcome in both primary and metastatic melanomas.47,50 It was also associated with tumor thickness, ulceration and reduced disease-free survival in primary melanomas.47 c-myc, particularly, was able to discriminate prognosis in high-risk melanoma patients with thick lesions (> 3 mm).47 Most importantly, overexpression of c-myc oncoprotein was a powerful prognostic marker for patients with regional nodal metastatic melanoma,50 in which the clinicopathological parameters were no longer of prognostic significance. Conversely, Boni et al.52 failed to find significant differences in c-myc reactivity between metastasizing and non-metastasizing cutaneous primary melanoma. They also found no correlation between c-myc expression and tumor thickness. It is generally accepted that proteases like plasminogen activators (PAs), primarily by degradation of the cancer-surrounding extracellular matrix, are involved in tumor cell invasion and metastasis.53 Urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA), serine proteinase inhibitors PAI-1 and PAI-2 and urokinase plasmogen activator receptor (uPAR) are members of the PA proteolytic system. High levels of uPA, PAI-1 expression and uPAR, measured by both IHC and ELISA, were repeatedly reported to be related to shorter disease-free and overall survival, whereas high tPA and PAI-2 levels were related to a favorable course of disease in some malignancies, such as breast carcinoma.54 Observations in experimental systems and on clinical material also pointed to a role for proteases in melanocytic tumor progression.55 uPA, uPAR, PAI-1 and PAI-2 appeared frequently in advanced primary and metastatic melanoma as well as atypical nevi, but not in benign nevi.56,57 Thus, uPA along with its receptor and inhibitors may be employed as markers of progression in melanocytic lesions and may provide a tool for the evaluation of atypia in nevi. In addition to the u-PA system, evidence also implicated the role of the t-PA system in melanoma progression and prognosis.54 Unlike the u-PA system, the extensive tPA expression of melanoma cells measured on paraffin tissue of clinical stage II melanoma with minimal (1.5 mm) thickness was reported to correlate with a favorable outcome.54 The best prognosis was related to lesions with 51–100% tPA tumor positivity, whereas the worst prognosis was related to lesions with intermediate (6–50%) tPA tumor cell expression.54 Moreover, tPA tumor cell positivity was an independent prognostic factor. The complex association between tPA expression and the outcome of disease in melanoma needs to be validated in further series. Another proteolytic enzyme system, matrix metalloproteinase (MMP), is also involved in the degradation of many different components of the extracellular matrix. MMPs and their specific tissue inhibitors (TIMPs) play an important role in cancer cell invasion and metastasis. Studies have shown that melanoma cells and melanoma tissue may express a number of MMP family members (MMP-1, MMP-2, MMP-9, MMP-13, and MT1-MMP) as well as their tissue inhibitors (TIMP-1, TIMP-2, and TIMP-3).58 Expression levels of several components of MMPs and TIMPs may increase in cutaneous melanoma progression.59–62 Taken together, these studies demonstrated a significant increase in the expression of MMP-1, MMP-2, MMP-13, MT1-MMP, TIMP-1, TIMP-2 and TIMP-3 in human melanoma during progression from in situ to metastasic disease.60–62 No MMP-2 expression was found in common nevi or atypical nevi.62 These findings suggest that MMPs and their inhibitors are required for melanoma invasion and metastasis. An inverse relationship between expression of MMP-9 and melanoma progression was found,63 with MMP-9 expression being detected only in the radial growth phase and absent in the vertical growth phase of primary melanoma and melanoma metastases. These studies, in general, demonstrate that MMPs and TIMPs play an important role in melanoma progression. Additionally, expression of MMP-2 has been found to correlate with unfavorable prognoses in male patients,64 and MMP-2 positivity in primary and subcutaneous melanoma lesions has been correlated with hematogenous metastasis.60 However, comprehensive studies of the MMP profile in large defined series of patients are needed to further evaluate the prognostic significance of individual MMPs. In addition to extracellular matrix-degrading activity, invasive melanoma cells must develop the ability to migrate through the dermis for tumor progression to occur. This ability requires a variety of adhesion molecules, motility factors, and homing receptors. Recently, several classes of cell adhesion molecules, including the integrins, cadherin, members of the immunoglobulin superfamily and CD44, have been shown to be key components in the metastatic cascade and to be prognostically valuable in cutaneous melanoma. Integrins are heterodimeric transmembrane glycoproteins composed of non-covalently bound α and β subunits that together form a functional cell adhesion receptor, and are involved in cell–cell and cell–extracellular matrix interactions. Because of their diverse functions, they have been implicated in tumor progression in many malignancies and also have been found to play a role in human melanoma progression and metastasis.65 In studies of human melanocytic lesions, both β1 and β3 integrin expressions have been linked to melanoma progression and metastasis.31,64–70 The collective data from these investigations suggest that the expression of β3 integrin, mainly αvβ3 integrin, as well as β1 integrin (mainly α2β1 and α3β1) progressively increases in the progression from benign nevi to malignant melanoma to metastatic melanoma. These studies emphasized that the expression of these integrins was absent or low in most benign nevi, except for Spitz nevi that strongly expressed β3 integrin.66 In primary melanoma, expression of β3 integrin was absent or low in the non-tumorigenic radial growth phase.70 In contrast, the expression of β1 and β3 integrins was higher in the vertical growth phase and in most metastatic melanomas.31,64–71 The expression of αvβ3 increased with tumor thickness and was associated with disease recurrence.70,71 However, studies of β integrin expression on clinical prognosis in melanoma are limited,31,68 and the diagnostic utility may be limited because of the strong expression of some integrins in Spitz nevi.66 In primary melanoma, high expression of both β1 and β3 integrins was associated with poor prognosis, with a worse prognosis in β3-positive patients who were more likely to die of disease31 and had significantly decreased disease-free survival.71 Moreover, individual integrin expression in primary melanomas may indicate different sites of metastasis.31β3 integrin was associated with subsequent lung metastasis,31 and β1 integrin with lymph node involvement.31,64 In contrast to primary melanoma, β1 integrin expression plays a different role for metastatic melanoma in predicting prognosis.68 Patients with β1-positive metastatic tumors had significantly longer disease-free survival and overall survival.68 In summary, αvβ3 integrin plays an important role during the transition from radial to vertical growth phase of primary melanoma; β1 and β3 are markers of poor prognosis in patients with primary melanoma; and the presence of β1 integrin in metastatic melanoma is associated with better survival. CD44 is a structurally variable and multifunctional cell surface glycoprotein found on most cell surfaces and is involved in a cell adhesion-dependent process. It forms the major cellular receptor for its ligand-hyaluronic acid (HA) of the extracellular matrix.72 The protein exists in a standard form (CD44H/CD44s) and at least 10 isoforms (v1–v10). Previous experimental data suggest that CD44 and HA enhance growth and metastatic capacity of melanoma cells,73 but the clinical significance has not been confirmed in other reports.74–78 CD44 was uniformly expressed in very high levels in benign melanocytic nevi, dysplastic nevi and melanoma in situ.74,75 In contrast, although virtually all melanomas expressed CD44, an inverse correlation in the levels of CD44s expression with increasing tumor thickness and invasiveness was found in primary melanoma74–77 and in metastatic melanomas,74,75 but no definite correlation between isoform CD44v expression and primary melanoma progression was found.74,75 Furthermore, metastases exhibited a significantly weaker or absent staining for CD44s compared with primary melanoma, although diminished expression of CD44s was observed in both.74,75 However, metastases could not be distinguished from primary lesions based on their CD44 immunostaining pattern.76 These data suggest a possible role for the downregulation of CD44s in modulating the biological behavior of malignant melanoma. Two studies addressed the prognostic value of CD44 expression in cutaneous melanoma. One study showed that patients having tumors with a high level of CD44 expression (> 2+ staining) experienced a significantly reduced 5-year survival rate compared with those having low levels of CD44 expression.78 In this study, the high level of CD44H/S predicted metastasis in patients with tumor thickness less than 0.7 mm. Conversely, another study77 demonstrated that reduced cell surface CD44 (< 90% positive tumor cells) and HA (< 70% positive tumor cells) levels within primary melanomas correlated with subsequent disease progression and short survival. In addition, this study showed reduced levels of CD44s acted as an independent unfavorable prognostic factor in clinical stage I melanoma. The conflicting results warrant further studies to confirm the usefulness of CD44s as a prognostic factor. Likewise, other cell adhesion molecules have also been implicated in tumor progression in cutaneous melanoma. The melanoma cell adhesion molecule (Mel-CAM), also known as MUC18, is a member of the immunoglobulin supergene family. Experimental studies suggest that MUC18 expression confers metastatic potential and increased tumorigenicity to human melanoma cells.79 It was shown that MUC18 was expressed in all primary and metastatic melanomas studied,80,81 and the expression of MUC18 in melanoma correlated with tumor thickness and with metastatic potential.82 However, MUC18 is not specific for melanoma. It has been reported to be expressed in many malignant tumors80 and, to date, no study has been done to correlate the expression of MUC18 and prognosis of melanoma. Intercellular adhesion molecule-1 (ICAM-1) is a cell adhesion molecule that is found on many cell types, including tumor cells. Expression of ICAM-1 has been shown to be associated with melanoma progression. ICAM-1 expression is stronger and more frequent in malignant than in benign melanocytic lesions and is significantly associated with tumor thickness in primary melanoma.71,81,83 Within malignant lesions, the expression of ICAM-1 was significantly higher in metastatic lesions than in primary melanomas.84 Moreover, elevated ICAM-1 expression has been shown to be a significant marker of poor prognosis in stage I tumors and metastatic melanoma.71,80,83 Cadherin constitutes a large family of Ca2+-dependent cell adhesion molecules mediating predominantly homophilic interactions, which include E (epithelial), P (placental), and N (neural) cadherins. The most intriguing observations regarding cadherin expression and melanoma progression have come from studies of the expression of E-cadherin and appear to be complex. E-cadherin is used by epidermal melanocytes to interact with neighboring keratinocytes, and loss of expression of E-cadherin has been linked to tumor progression in various carcinomas.85 Regarding melanoma progression, in vitro studies have shown that E-cadherin is expressed in cultured melanocytes and nevus cells and lost in invasive, metastatic melanoma cells.85 However, studies of E-cadherin expression in melanocytic lesions revealed a complex pattern. Unexpectedly, the expression of E-cadherin was increased with invasive tumor growth in advanced primary and metastatic melanoma,85,86 which was converse to the finding in vitro. Downregulation of E-cadherin expression was observed in early primary melanomas and in radial growth phase,85,86 whereas some expression could be observed in advanced tumors, vertical growth phase melanoma and metastatic melanoma.85,86 No study has focused on its prognostic value. Telomeres are the chromosomal end regions composed of tandem repeats of the sequence TTAGGG in vertebrates. During successive cell division of mortal cells, the length of the telomeres decreases. It has been suggested that this process is responsible for cellular senescence and immortalization.87 Telomerase, a ribonucleoprotein that adds repeated units of TTAGGG to the end of telomeres, confers extended life span to cells, and the majority of human malignancies exhibit telomerase activity (TA), whereas most normal tissues do not.87 The evaluation of TA has been proposed for diagnostic and therapeutic purposes in human cancer.87 In the skin, TA has been shown to be low in the epidermal basal layer and in the bulge region of hair follicles, in UV-exposed skin and in some inflammatory dermatoses. In cutaneous tumors, telomerase levels have been found to be high in basal cell carcinoma, and low in squamous cell carcinoma. TA has been detected in melanoma cell lines88 and melanoma tissues in a number of studies,89–93 by means of a modified telomeric repeat amplification protocol (TRAP) assay. Taken together, these results indicate that TA increases from benign melanocytic nevi to atypical nevi and further to malignant melanoma and metastatic melanoma, and therefore may play a role in tumor initiation and progression.89–93 Although TA was not detected in all cases,92 its expression was demonstrated in most primary and metastatic melanomas,89–93 and it showed the highest values in metastases.90–93 Furthermore, TA increased significantly with melanoma level and thickness.91,93 Clinicopathological correlations showed an association between high TA and early metastatic spread in melanomas.90 The significant increase of TA with tumor progression suggests its potential prognostic role in cutaneous melanoma. Microphthalmia-associated transcription factor (Mitf), the human homolog of the mouse microphthalmia (mi) gene product, is a nuclear protein critical for the embryonic development and postnatal viability of melanocytes. Mitf was initially reported to be a specific marker of melanocytic skin lesions.94,95 With the exception of desmoplastic melanomas, all primary and metastatic cutaneous melanomas stained positively for Mitf, even in those cases that were negative for HMB-45 and S-100.94,95 However, in another study, only 82.5% of melanomas stained positively for Mitf.96 Although the diagnostic value of Mitf in primary melanocytic skin lesions and melanomas is not promising, a recent study97 suggested that Mitf might be a new prognostic marker in patients with intermediate-thickness melanoma. The data in this study showed that Mitf expression was associated with significantly prolonged overall survival and disease-free survival in patients with Mitf-positive melanoma. Semi-quantitative immunocytochemical analysis has shown that the higher the number of melanoma cells with Mitf expression in a given primary tumor, the better the prognosis. In addition, low or lack of Mitf expression in primary lesions was an indicator of regional node metastasis. Patients with > 50% Mitf expression had a significantly lower incidence of nodal disease.97 Recently, a new cell surface protein, Mr 55,000, found on αvβ3-negative metastatic melanoma variants, was identified. This protein plays a critical role in the malignant phenotype of human melanoma.98 The monoclonal antibody (LY1 or p55) against Mr 55,000 cell surface protein was studied on archival tissues of human melanomas and nevi. LY1 stained none of the benign melanocytic lesions or radial growth phase melanomas. In striking contrast, LY1 selectively stained melanocytes derived from the vertical growth phase of many primary melanomas and metastatic melanomas. Thus, this molecule may represent a new metastatic risk marker in human melanoma, which needs to be confirmed by additional studies. A broad variety of molecules synthesized, secreted or shed into the blood, either directly by melanoma cells or as an indirect response of the patient's immune system, have been studied as markers of tumor progression (Table 1). These include melanoma-associated antigens, melanin-related metabolites, adhesion molecules and cytokines. In recent years, two new melanoma-associated antigens markers, S100-β and MIA (melanoma inhibitory activity), have generated great interest regarding their clinical use as serum markers to monitor therapy and detect disease progression in patients with malignant melanomas. As a melanoma -associated molecule, S-100 protein is a 21-kDa calcium-binding acidic protein, composed of a heterodimer of two isomeric subunits, α and/or β, first described in cells of neuroendocrine origin. Its immunohistochemical detection is widely used in the histopathological diagnosis of cells of melanocytic origin. Recently, several studies have revealed the clinical significance of the quantification of the S-100b subunit in serum. S-100-β serum levels can be determined by an immunoradiometric assay (IRMA), or a luminoimmunometric assay (LIA). LIA assay is currently more frequently used because of its good reproducibility and improved sensitivity over IRMA. Although results vary due to different cut-off level of serum S-100-β, ranging from 0.114 to 0.2 mg/l, it is clear that serum S-100 levels are elevated in melanoma patients in a clinical stage-dependent fashion.99–103 The proportion of patients with increased S-100 serum levels was lowest in stage I/II melanoma (0–12%)99–101 and highest in stage IV (48–100%).99,100,102 In addition, serum S-100 levels were found to correlate with the extent of metastatic spread reflecting tumor burden.101,104 Since increased serum S-100-β levels have rarely been found in healthy people99,100 and in gastrointestinal carcinomas,105 and because it has lo" @default.
W2015203796 created "2016-06-24" @default.
W2015203796 creator A5006935079 @default.
W2015203796 creator A5009752673 @default.
W2015203796 creator A5086264469 @default.
W2015203796 date "2002-07-01" @default.
W2015203796 modified "2023-10-18" @default.
W2015203796 title "New prognostic factors of cutaneous melanoma: a review of the literature" @default.
W2015203796 cites W106986414 @default.
W2015203796 cites W1486621660 @default.
W2015203796 cites W1493098692 @default.
W2015203796 cites W1542950394 @default.
W2015203796 cites W1561412137 @default.
W2015203796 cites W1617231590 @default.
W2015203796 cites W1638772292 @default.
W2015203796 cites W16739424 @default.
W2015203796 cites W1869672968 @default.
W2015203796 cites W1892164682 @default.
W2015203796 cites W1901112984 @default.
W2015203796 cites W1953419682 @default.
W2015203796 cites W1963957294 @default.
W2015203796 cites W1965838399 @default.
W2015203796 cites W1967475743 @default.
W2015203796 cites W1968122151 @default.
W2015203796 cites W1968451976 @default.
W2015203796 cites W1968697963 @default.
W2015203796 cites W1969869532 @default.
W2015203796 cites W1971855510 @default.
W2015203796 cites W1972599894 @default.
W2015203796 cites W1972679476 @default.
W2015203796 cites W1974188559 @default.
W2015203796 cites W1976546353 @default.
W2015203796 cites W1978113416 @default.
W2015203796 cites W1979815195 @default.
W2015203796 cites W1979873958 @default.
W2015203796 cites W1980001739 @default.
W2015203796 cites W1982932552 @default.
W2015203796 cites W1988407228 @default.
W2015203796 cites W1989056136 @default.
W2015203796 cites W1990699805 @default.
W2015203796 cites W1992842427 @default.
W2015203796 cites W1994089726 @default.
W2015203796 cites W1994169870 @default.
W2015203796 cites W1996568527 @default.
W2015203796 cites W1999360347 @default.
W2015203796 cites W1999824679 @default.
W2015203796 cites W2000971601 @default.
W2015203796 cites W2000994426 @default.
W2015203796 cites W2001616358 @default.
W2015203796 cites W2003134209 @default.
W2015203796 cites W2003920155 @default.
W2015203796 cites W2005129214 @default.
W2015203796 cites W2007059611 @default.
W2015203796 cites W2010241928 @default.
W2015203796 cites W2012685443 @default.
W2015203796 cites W2016427872 @default.
W2015203796 cites W2016508329 @default.
W2015203796 cites W2018898699 @default.
W2015203796 cites W2024782914 @default.
W2015203796 cites W2027499645 @default.
W2015203796 cites W2030447134 @default.
W2015203796 cites W2031895416 @default.
W2015203796 cites W2033173676 @default.
W2015203796 cites W2033552578 @default.
W2015203796 cites W2035088098 @default.
W2015203796 cites W2035510366 @default.
W2015203796 cites W2035757622 @default.
W2015203796 cites W2037523875 @default.
W2015203796 cites W2037987950 @default.
W2015203796 cites W2039286536 @default.
W2015203796 cites W2040084628 @default.
W2015203796 cites W2042750345 @default.
W2015203796 cites W2047987451 @default.
W2015203796 cites W2052139455 @default.
W2015203796 cites W2052368125 @default.
W2015203796 cites W2054288725 @default.
W2015203796 cites W2060327742 @default.
W2015203796 cites W2062130696 @default.
W2015203796 cites W2064217869 @default.
W2015203796 cites W2064505857 @default.
W2015203796 cites W2065643086 @default.
W2015203796 cites W2066140820 @default.
W2015203796 cites W2066749889 @default.
W2015203796 cites W2069040571 @default.
W2015203796 cites W2069330945 @default.
W2015203796 cites W2071034864 @default.
W2015203796 cites W2072859571 @default.
W2015203796 cites W2075329621 @default.
W2015203796 cites W2076247082 @default.
W2015203796 cites W2078958377 @default.
W2015203796 cites W2080323885 @default.
W2015203796 cites W2081253148 @default.
W2015203796 cites W2081886264 @default.
W2015203796 cites W2082780899 @default.
W2015203796 cites W2083574998 @default.
W2015203796 cites W2084480843 @default.
W2015203796 cites W2084712389 @default.
W2015203796 cites W2088055822 @default.